KR100886783B1 - N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 - Google Patents
N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 Download PDFInfo
- Publication number
- KR100886783B1 KR100886783B1 KR1020060052702A KR20060052702A KR100886783B1 KR 100886783 B1 KR100886783 B1 KR 100886783B1 KR 1020060052702 A KR1020060052702 A KR 1020060052702A KR 20060052702 A KR20060052702 A KR 20060052702A KR 100886783 B1 KR100886783 B1 KR 100886783B1
- Authority
- KR
- South Korea
- Prior art keywords
- trail
- peg
- modified
- conjugate
- terminus
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
Abstract
Description
ILz-hTRAIL | PEG5K-ILz-hTRAIL | |
AUC(ng.hr/㎖) | 7.71 ± 1.10 | 7628.2 ± 321.6 |
Cmax(ng/㎖) | 3.38 ± 0.48 | 298.3 ± 24.8 |
Tmax(hr) | 0.96 ± 0.19 | 19.0 ± 1.0 |
T1/2(hr) | 0.79 ± 0.01 | 24.5 ± 4.0 |
Claims (31)
- 삼량체 형성 도메인을 N-말단에 포함하는 삼량체 형태의 TRAIL 중 하나의 단량체 N-말단에 PEG를 특이적으로 결합시킨 것을 특징으로 하는, N-말단이 수식된 PEG-TRAIL 결합체.
- 삭제
- 제1항에 있어서, 상기 PEG 는 직선형 또는 가지형인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 제1항에 있어서, 상기 PEG는 메톡시폴리에틸렌 글리콜 숙신이미딜 프로피오네이트, 메톡시폴리에틸렌 글리콜 N-히드록시숙신이미드, 메톡시폴리에틸렌 글리콜 알데히드, 메톡시폴리에틸렌 글리콜 말레이미드 및 다중가지형 폴리에틸렌 글리콜로 이루어지는 군으로부터 선택되는 어느 하나 이상인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 제4항에 있어서, 상기 PEG는 메톡시폴리에틸렌 글리콜 알데히드인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 제1항에 있어서, 상기 PEG의 분자량은 1,000 ~ 40,000의 범위에서 선택되는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 제6항에 있어서, 상기 PEG의 분자량은 5,000 ~ 40,000의 범위에서 선택되는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 제1항에 있어서, 상기 TRAIL 은 천연 또는 유전자 재조합으로 얻어진 TRAIL 인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 삭제
- 제1항에 있어서, 상기 TRAIL 은 1-281의 아미노산 서열을 갖는 인간 TRAIL 인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 제10항에 있어서, 상기 TRAIL 은 114번 알지닌부터 281번 글리신까지의 아미노산 서열을 갖는 인간 TRAIL 인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 제1항에 있어서, 상기 삼량체 형성 도메인은 이소루신 지퍼인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체.
- 삼량체 형성 도메인을 N-말단에 포함하는 삼량체 형태의 TRAIL의 N-말단 아민과 PEG의 알데하이드기를 환원제 하에서 반응시키는 단계를 포함하는, 제1항의 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 삭제
- 제13항에 있어서, 상기 PEG 는 직선형 또는 가지형인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제13항에 있어서, 상기 PEG는 메톡시폴리에틸렌 글리콜 숙신이미딜 프로피오네이트, 메톡시폴리에틸렌 글리콜 N-히드록시숙신이미드, 메톡시폴리에틸렌 글리콜 알데히드, 메톡시폴리에틸렌 글리콜 말레이미드 및 다중가지형 폴리에틸렌 글리콜로 이루어지는 군으로부터 선택되는 어느 하나 이상을 사용하는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제13항에 있어서, 상기 PEG는 1,000 내지 40,000의 분자량을 갖는 것을 사용하는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제17항에 있어서, 상기 PEG는 5,000 내지 40,000의 분자량을 갖는 것을 사용하는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제13항에 있어서, PEG/TRAIL 의 반응 몰비는 2 ~ 10인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제13항에 있어서, 상기 PEG/TRAIL 의 반응 몰비는 5 ~ 7.5인 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제13항에 있어서, 상기 TRAIL 은 천연 또는 유전자 재조합으로 얻어진 TRAIL 인 것을 사용하는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 삭제
- 제21항에 있어서, 상기 TRAIL 은 1-281의 아미노산 서열을 갖는 인간 TRAIL 인 것을 사용하는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제23항에 있어서, 상기 TRAIL 은 114번 알지닌부터 281번 글리신까지의 아미노산 서열을 갖는 인간 TRAIL 인 것을 사용하는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제13항에 있어서, 상기 삼량체 형성 도메인은 이소루신 지퍼를 사용하는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제13항에 있어서, 상기 환원제는 NaCNBH3 및 NaBH4로 이루어지는 군으로부터 선택되는 어느 1 이상을 사용하는 것을 특징으로 하는 N-말단이 수식된 PEG-TRAIL 결합체의 제조방법.
- 제1항의 N-말단이 수식된 PEG-TRAIL 결합체를 유효성분으로 함유하는, 대장암, 신경교종암, 폐암, 전립선암, 뇌종양 또는 다발성 골수종 암종의 예방 및 치료제.
- 삭제
- 삭제
- 제1항의 N-말단이 수식된 PEG-TRAIL 결합체를 유효성분으로 함유하는 자가면역 질환의 예방 및 치료제.
- 제30항에 있어서, 상기 자가면역 질환은 실험적 자가 면역 뇌수막염, 류마티스 관절염 및 제1형 당뇨병을 포함하는 자가면역 질환의 예방 및 치료제.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060052702A KR100886783B1 (ko) | 2006-06-12 | 2006-06-12 | N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 |
PCT/KR2007/002825 WO2007145457A1 (en) | 2006-06-12 | 2007-06-12 | N-terminal modified peg-trail, method for preparing and uses thereof |
DK07746877.5T DK2026842T3 (en) | 2006-06-12 | 2007-06-12 | N-terminal modified PEG-TRAIL, method of manufacture and uses thereof |
US12/304,121 US9321825B2 (en) | 2006-06-12 | 2007-06-12 | N-terminal modified PEG-TRAIL |
EP07746877.5A EP2026842B1 (en) | 2006-06-12 | 2007-06-12 | N-terminal modified peg-trail, method for preparing and uses thereof |
ES07746877.5T ES2610576T3 (es) | 2006-06-12 | 2007-06-12 | PEG-TRAIL modificado en N-terminal, procedimiento de preparación y usos del mismo |
US15/138,109 US10046059B2 (en) | 2006-06-12 | 2016-04-25 | Methods of administering an N-terminal modified PEG-TRAIL |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060052702A KR100886783B1 (ko) | 2006-06-12 | 2006-06-12 | N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070118492A KR20070118492A (ko) | 2007-12-17 |
KR100886783B1 true KR100886783B1 (ko) | 2009-03-04 |
Family
ID=38831930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060052702A KR100886783B1 (ko) | 2006-06-12 | 2006-06-12 | N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
US (2) | US9321825B2 (ko) |
EP (1) | EP2026842B1 (ko) |
KR (1) | KR100886783B1 (ko) |
DK (1) | DK2026842T3 (ko) |
ES (1) | ES2610576T3 (ko) |
WO (1) | WO2007145457A1 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100886783B1 (ko) | 2006-06-12 | 2009-03-04 | 성균관대학교산학협력단 | N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 |
US20100105620A1 (en) * | 2008-10-10 | 2010-04-29 | Anaphore, Inc. | Polypeptides that bind Trail-R1 and Trail-R2 |
WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
KR20150133576A (ko) * | 2014-05-20 | 2015-11-30 | 삼성전자주식회사 | 화학적 개질된 표적화 단백질 및 그의 이용 |
WO2016074033A1 (en) * | 2014-11-13 | 2016-05-19 | The Heart Research Institute Ltd | Tumour necrosis factor (tnf)-related apoptosis-inducing ligand (trail): compositions and methods for treating wound healing |
WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
WO2017177148A1 (en) | 2016-04-07 | 2017-10-12 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998031383A1 (en) * | 1997-01-15 | 1998-07-23 | Phoenix Pharmacologics, Inc. | Modified tumor necrosis factor |
KR20020010363A (ko) * | 2000-07-29 | 2002-02-04 | 박명옥 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
WO2004001009A2 (en) * | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
KR20060129889A (ko) * | 2005-06-13 | 2006-12-18 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329336B1 (en) | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US6908963B2 (en) * | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
AU2003273300A1 (en) | 2002-09-06 | 2004-03-29 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
WO2005082934A2 (en) * | 2004-02-20 | 2005-09-09 | Five Prime Therapeutics, Inc. | Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use |
US20080182783A1 (en) | 2004-10-18 | 2008-07-31 | Novo Nordisk A/S | Growth Hormone Conjugates |
US20060228352A1 (en) | 2005-02-24 | 2006-10-12 | Schoenberger Stephen P | TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL |
KR100886783B1 (ko) | 2006-06-12 | 2009-03-04 | 성균관대학교산학협력단 | N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 |
WO2012018616A2 (en) | 2010-07-26 | 2012-02-09 | Anaphore, Inc. | Polypeptides that bind trail-r1 and trail-r2 |
US20130101553A1 (en) | 2011-04-18 | 2013-04-25 | The Regents Of The University Of California | Inducing inactivation of fibrogenic myofibroblasts |
-
2006
- 2006-06-12 KR KR1020060052702A patent/KR100886783B1/ko active IP Right Grant
-
2007
- 2007-06-12 WO PCT/KR2007/002825 patent/WO2007145457A1/en active Application Filing
- 2007-06-12 EP EP07746877.5A patent/EP2026842B1/en active Active
- 2007-06-12 ES ES07746877.5T patent/ES2610576T3/es active Active
- 2007-06-12 US US12/304,121 patent/US9321825B2/en active Active
- 2007-06-12 DK DK07746877.5T patent/DK2026842T3/en active
-
2016
- 2016-04-25 US US15/138,109 patent/US10046059B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998031383A1 (en) * | 1997-01-15 | 1998-07-23 | Phoenix Pharmacologics, Inc. | Modified tumor necrosis factor |
KR20020010363A (ko) * | 2000-07-29 | 2002-02-04 | 박명옥 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
WO2004001009A2 (en) * | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
KR20060129889A (ko) * | 2005-06-13 | 2006-12-18 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
Also Published As
Publication number | Publication date |
---|---|
EP2026842B1 (en) | 2016-10-12 |
EP2026842A4 (en) | 2011-05-18 |
US10046059B2 (en) | 2018-08-14 |
US20090203599A1 (en) | 2009-08-13 |
WO2007145457A1 (en) | 2007-12-21 |
EP2026842A1 (en) | 2009-02-25 |
DK2026842T3 (en) | 2017-01-23 |
US20160279253A1 (en) | 2016-09-29 |
ES2610576T3 (es) | 2017-04-28 |
US9321825B2 (en) | 2016-04-26 |
KR20070118492A (ko) | 2007-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100886783B1 (ko) | N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 | |
US10526638B2 (en) | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof | |
JP6572212B2 (ja) | 治療用の改変霊長類l−メチオニナーゼ | |
JP7164247B2 (ja) | アシル化glp-1誘導体 | |
KR20140107616A (ko) | 사람 아르기나제 및 페길화된 사람 아르기나제 및 그의 적용 | |
CN108066772A (zh) | 靶向tacstd2的抗体与药物偶联体(adc)分子 | |
WO2011011973A1 (zh) | 抗cd20抗体fab片段与力达霉素的融合蛋白、制备方法及其用途 | |
TWI798209B (zh) | 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途 | |
CN113024660A (zh) | 酰化的glp-1衍生物 | |
CN112218644A (zh) | 人类犬尿氨酸酶及其用途 | |
NZ533849A (en) | Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon | |
KR101095396B1 (ko) | 암 표적지향형 트랜스페린-폴리에틸렌 글리콜이 수식된 트레일, 이의 제조 및 용도 | |
RU2753191C2 (ru) | Новый рекомбинантный аналог гормона роста пролонгированного действия | |
CN117106035B (zh) | 一种肿瘤靶向多肽、多肽偶联药物及制备与应用 | |
US20220275357A1 (en) | Capsule protein and multimeric complex composition thereof, and pharmaceutical composition using same | |
KR20090118626A (ko) | 알지디-폴리에틸렌 글리콜이 수식된 트레일, 이의제조방법, 및 용도 | |
KR20220103944A (ko) | Peg화 키뉴레니나제 효소 및 암 치료를 위한 그의 용도 | |
CN115605495A (zh) | 用于预防或治疗癌症的药物组合物 | |
EP4237000A1 (en) | Two-domain multimeric fusion proteins | |
TW202247856A (zh) | 新穎之三重升糖素/glp-1/gip受體促效劑及其用途 | |
CN117384273A (zh) | 一种聚乙二醇修饰的il-2衍生物及其应用 | |
CN117379561A (zh) | 一种靶向人igsf9的抗体偶联药物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130111 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140106 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150115 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160215 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161228 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171227 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181205 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20200110 Year of fee payment: 12 |